1. Palumbo A, Bringhen S, Rossi D,Cavalli M, Larocca A, Ria R, et. al.
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan- prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101-9. 2. Mateos M-V, Oriol A, Lopez JM, Teruel AI, Guia ALDL, Lopez J, et al. GEM 2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 2014;124912):1887-93. 3. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma : IFM 01/01 trial. J Clin Oncol. 2009;22:3664-70. 4. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksa M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239-47. 5. Ludwig H, Hajek R, Tthov E et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113:34353442. 6. Kyle RA, Rajkumar SV. Drug therapy multiple myeloma. N Engl J Med. 2004;351:1860-73. 7. Genadieva-Stavric S, Cavallo F, Palumbo A. New approaches to management of multiple myeloma. Curr Treat Opt Oncol 2014;15(2):157- 70. 8. Cavo M, Rajkumar SV, Palumbo A, Moraeu P, Orlowski R, Blade J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation. Blood 2011;11(23):6063-73. 9. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niezvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care for myeloma 39
patients who are not eligible for standard autologous stem-cell
transplantation. J Clin Oncol. 2014;32:1-17.
10. Rhee FV, Anaissie E, Angtuaco E, Bartel T, Epstein J, Nair B, et al.
Myeloma. In: Kaushansky K, Lichtman MA, Beuler E, Kipps TJ, Seligsohn U, Prchal JT, editors. Williams Hematology. 8th ed. New York: Mc Graw Hill; 2010.p.1645-81. 11. Tadjoedin H, Reksodiputro AH, Toruan T, Kosasih AA, Supandiman I, Sumantri R, et al. Multiple myeloma in Indonesia. Indonesian J Cancer. 2011;2(5):76-81. 12. Saraf S, Patel P, Rondelli D. Epidemiology, biology, and outcome in multiple myeloma patients in different geographical areas of the world. J Adv Intern Med 2012;01:20-32. 13. Al-Farsi K. Multiple myeloma : An update. Oman Med J. 2013;1(28):3-11. 14. Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Am J Hematol. 2014;89:751-6. 15. Sinuraya ES. Registrasi Kanker Rumah Sakit Kanker Dharmais tahun 1993-2010. 16. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120 Suppl 12:40-61. 17. Khan MM, Mori Mitsuru, Sakauchi Fumio, Matsuo K, Ozasa K, Tamakoshi A. Risk factor for multiple myeloma: Evidence from the Japan Collaborative Cohort (JACC) Study. 2006. Asian Pac J Cancer Prev. 2006;7:575-81 18. Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med 2011;364:1046-60. 19. Tan D, Chng WJ, Chou T, Nawarawong SY, Hwang SY, Chim CS, et al. Management of multiple myeloma in Asia: resource-startified guidelines. Lancet 2013;14:571-9. 20. Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 2013;98:980-7. 40
21. Chanan-Khan AA, Giralt S. Importance of achieving a complete response
in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;15(28):2612-24. 22. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;5(111):2516-20. 23. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025-31. 24. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;20:3076-84. 25. Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-73. 26. Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory drugs action in the treatment of multiple myeloma. Acta Biochim Biophys Sin. 2014;46(3):240-7. Anak ayammm suka makan
Corporate Governance, Corporate Profitability Toward Corporate Social Responsibility Disclosure and Corporate Value (Comparative Study in Indonesia, China and India Stock Exchange in 2013-2016) .